دورية أكاديمية
Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?
| العنوان: | Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment? |
|---|---|
| المؤلفون: | Korkmaz ET; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey., Aydın O; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey., Mungan D; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey., Sin BA; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey., Demirel YS; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey., Bavbek S; Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey. |
| المصدر: | European annals of allergy and clinical immunology [Eur Ann Allergy Clin Immunol] 2024 Jan; Vol. 56 (1), pp. 26-33. Date of Electronic Publication: 2022 Jul 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Country of Publication: Italy NLM ID: 101466614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1764-1489 (Print) Linking ISSN: 17641489 NLM ISO Abbreviation: Eur Ann Allergy Clin Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Milano : EDRA LSWR Original Publication: Paris : Meditions Carline |
| مواضيع طبية MeSH: | Aspergillosis, Allergic Bronchopulmonary*/diagnosis , Aspergillosis, Allergic Bronchopulmonary*/drug therapy , Asthma*/diagnosis , Asthma*/drug therapy , Anti-Asthmatic Agents*/therapeutic use, Humans ; Adult ; Middle Aged ; Aged ; Omalizumab/therapeutic use ; Drug Tapering ; Retrospective Studies |
| مستخلص: | Summary: Background. Allergic bronchopulmonary aspergillosis (ABPA) is an endotype of severe asthma which frequently needs biologics for their steroid sparing effect. We aimed to evaluate the outcomes of reducing the omalizumab dose in patients with ABPA who were on long-term omalizumab treatment. Methods. Once asthma was controlled, two approaches were used to reduce total monthly omalizumab dose: 1) both extending dose intervals from 2 to 4 weeks and decrease omalizumab dose, 2) to reduce omalizumab dose while keeping dose intervals stable. Results. Thirteen patients with ABPA (8F/5M, mean age 53.4 ± 13.0 years) were included. Pre-omalizumab, mean numbers of attacks and hospitalizations were 2.5 ± 1.5 and 1.3 ± 0.8, mean oral corticosteroid (OCS, as methylprednisolone) dose was 12.2 ± 10.4 mg daily. First omalizumab dose reduction was made to all patients at a median time of 35 months (min 13, max 47). The 2 nd dose reduction was made in four patients at median of 23.5 months. Mean OCS decreased to 0.69 ± 0.95 mg/day (p = 0.001) in the 1st year of omalizumab, could be stopped in 11 patients in last evaluation. Attacks/hospitalizations decreased significantly to 0.31 ± 0.86 and 0, respectively, in the 1st year of omalizumab. Total omalizumab dose was reduced by median 40% (min 20, max 60) in 1st intervention and 50% (min 20, max 67) after 2nd intervention. After omalizumab dose reduction, asthma control did not deteriorate and there was no need to increase the omalizumab or OCS-dose. Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled. |
| فهرسة مساهمة: | Keywords: ABPA; Asthma; asthma control; omalizumab; omalizumab dose reduction |
| المشرفين على المادة: | 2P471X1Z11 (Omalizumab) 0 (Anti-Asthmatic Agents) |
| تواريخ الأحداث: | Date Created: 20220719 Date Completed: 20240117 Latest Revision: 20240117 |
| رمز التحديث: | 20240117 |
| DOI: | 10.23822/EurAnnACI.1764-1489.261 |
| PMID: | 35850503 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!